Recompete of contract no. 75N95022C00004 (N01DA-22-8959) with VCU
Past New Requirement Updated
- Agency
-
National Institutes of Health
Department of Health and Human Services
- Solicitation expected
- Estimated value
- $7,000,000 to $13,000,000
- Set-aside
- No set-aside
Forecast facts
- Anticipated award
- NAICS code
- 541715 Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
- Points of contact
Forecast details come from HHS's procurement forecast. Agencies' dates and values are estimates.
About this forecast
The National Institutes of Health forecasts a New Requirement for the competitive recompete of contract 75N95022C00004 (N01DA-22-8959) with Virginia Commonwealth University, with an estimated solicitation release of 2026-07-01 and an estimated award on 2027-02-01. The contract supports rodent studies for medications discovery and abuse liability testing, including evaluations of compound effects on opiate withdrawal, nicotine withdrawal, hedonic/anhedonic effects using intracranial self-stimulation, and non-reinforced responding in food-trained rats, which provide controls for relapse model studies under a separate contract. The requirement calls for flexibility to establish new procedures and reassign laboratory staff across testing types based on NIDA's needs, falls under NAICS 541715, and uses no set-aside.
The estimated award value range is $7.0 million to $13.0 million. NIH expects that additional funding will be required in some years and that appropriate options will be included in the statement of work. Points of contact are Joshua Lazarus, Contract Specialist, at josh.lazarus@nih.gov or +1-301-827-6923, and David White at whitedav@nida.nih.gov.
Forecast text
This is for the competitive renewal of contract 75N95022C00004 (N01DA-22-8959) with Virginia Commonwealth University. This contract supports a wide range of rodent studies for the purpose of medications discovery and has capacity for abuse liability testing. The contract supports studies evaluating the effects of compounds on opiate withdrawal, nicotine withdrawal, studies evaluating the hedonic/anhedonic effects of compounds using intracranial self-stimulation, and studies evaluating the effects of test compounds on non-reinforced responding in food-trained rats, providing the proper controls for "relapse model" studies conducted under a separate contract. A significant feature of the contract is the flexibility to establish new procedures and move laboratory staff from one type of testing to another based on NIDA's needs. We expect that additional funding will be required in some years and appropriate options will be included in the SOW
On GovTribe
Work this forecast
- Track it in your pipeline
- Find teaming partners
- Similar forecasts
- Ask GovTribe AI about this forecast